AngioDynamics has filed a lawsuit against Endovascular Engineering (E2) in the U.S. District Court for the District of ...

CEO Jim Clemmer highlighted strong Q3 performance with total revenue reaching $72 million, reflecting over 9% year-over-year growth. MedTech revenue grew by 22%, with continued success across ...

TCT 176: Randomized comparison of intracoronary lithotripsy and rotational atherectomy for the treatment of severely calcified vessels – ROTA.shock trial Receive the the latest news, research, and ...

Good morning and welcome to the AngioDynamics Fiscal Year 2025 Second Quarter Earnings Call. At this time all participants are in a listen-only mode. A question-and-answer session will follow the ...

"Our mechanical thrombectomy portfolio exhibited standout performance as commercial adoption continues to build with both AlphaVac and AngioVac." The company reported adjusted EBITDA of $1.8 million, ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Management stated, the raising guidance going forward, it is primarily being driven by what we're seeing in the Mechanical Thrombectomy and NanoKnife spaces. Stephen Trowbridge said, We expect both to ...

Revenue: Increased 8.9% to $78.4 million. Med Tech Revenue: $37.3 million, a 19% increase. Auryon Platform Revenue: $16.3 million, growing 17.9% year-over-year. Mechanical Thrombectomy Revenue: $11.5 ...